Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) Price Target at $20.00

Alto Neuroscience, Inc. (NYSE:ANRO) has been given an average rating of “Moderate Buy” by the eight ratings firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $20.00.

A number of research firms recently issued reports on ANRO. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Robert W. Baird decreased their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus decreased their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd.

Alto Neuroscience Stock Up 1.1 %

NYSE:ANRO opened at $3.79 on Friday. Alto Neuroscience has a 12 month low of $3.58 and a 12 month high of $24.00. The firm has a fifty day simple moving average of $6.06 and a 200-day simple moving average of $9.86. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. As a group, research analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. FMR LLC raised its position in shares of Alto Neuroscience by 1.4% in the third quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after acquiring an additional 32,040 shares during the period. Franklin Resources Inc. increased its stake in shares of Alto Neuroscience by 95.3% during the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock worth $13,965,000 after purchasing an additional 595,673 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Alto Neuroscience by 80.3% during the third quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after purchasing an additional 370,612 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Alto Neuroscience by 4.8% during the third quarter. Vestal Point Capital LP now owns 650,000 shares of the company’s stock worth $7,436,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Vanguard Group Inc. purchased a new stake in shares of Alto Neuroscience during the first quarter worth about $8,233,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.